Just one dose of the HPV vaccine may be enough to lower cancer rates - New Scientist News
Just one dose of the HPV vaccine may be enough to lower cancer rates - New Scientist News |
- Just one dose of the HPV vaccine may be enough to lower cancer rates - New Scientist News
- HealthWatch: Wipe Out HPV With New Vaccine - WeAreGreenBay.com
- HPV Testing & PAP Test Market Unit Sales to Witness Significant Growth in the Near Future - Market Reports
| Just one dose of the HPV vaccine may be enough to lower cancer rates - New Scientist News Posted: 29 Jul 2019 03:42 AM PDT  Matthew Busch for The Washington Post via Getty Images A single dose of the human papillomavirus (HPV) vaccine seems to be almost as good as two or three injections at preventing cervical cancer. The finding may make reaching the World Health Organization's goal of eliminating cervical cancer easier than initially thought. Many people catch HPV through sexual activity, but the body's immune system can usually wipe the virus out within a year or two. However, when HPV infections persist they can eventually cause cancer. The virus is responsible for more than 99 per cent of cervical cancers, as well as causing vaginal, vulval, anal and penile cancers, and genital warts. In 2007, Australia rolled out the world's first national HPV programme, providing girls in schools with three free shots of the vaccine each. The injection is now offered to boys too, and the vaccine – which has been improved to protect against nine strains of HPV – is now usually given in two doses.
AdvertisementTo understand how different doses of the vaccine affect the risk of developing cervical cancer, Julia Brotherton at the VCS Foundation in Australia and her colleagues analysed cervical screening data from a quarter of a million Australian women who were eligible for the vaccination. During the study, sexually active women were encouraged to have a Pap smear test every two years to screen for cellular changes on the cervix that might be a sign of cancer. Analysing registers of HPV vaccinations and cervical cancer cases, the team found that women who had received three doses of the vaccine were 41 per cent less likely to have these cellular changes – known as precancerous lesions – than unvaccinated women. Women who had been given one or two doses of the vaccine were, respectively, 35 and 39 per cent less likely than unvaccinated women to have these lesions. This suggests that even one dose of the vaccine can be enough to help lower the incidence of cervical cancer. Administering a one-dose vaccination campaign would be cheaper and easier to administer than a multi-dose programme. The finding could be particularly useful in developing nations, as these have the highest burden of cervical cancer but the least access to vaccines. Journal reference: Papillomavirus Research, DOI: 10.1016/j.pvr.2019.100177 More on these topics:  |
| HealthWatch: Wipe Out HPV With New Vaccine - WeAreGreenBay.com Posted: 10 Jul 2019 12:00 AM PDT  ANN ARBOR, Mich. (Ivanhoe Newswire) — Once someone is infected with the human papillomavirus or HPV, there's been absolutely nothing that cleared the infection until now. Researchers say they've had success in phase two trials of a new vaccine that helps the body rid itself of the virus. Free weekly e-mail on Medical Breakthroughs from Ivanhoe. To sign up: http://www.ivanhoe.com/ftk MEDICAL BREAKTHROUGHS TOPIC: WIPE OUT HPV WITH NEW VACCINE BACKGROUND: HPV stands for human papillomavirus. It's the most common sexually transmitted infection. HPV is usually harmless and goes away by itself, but some types can lead to cancer or genital warts. There's no cure for HPV. But there's a lot you can do to keep HPV from having a negative impact on your health. There are vaccines that can help protect you from ever getting certain types of HPV. Genital warts can be removed by your nurse or doctor. High-risk HPV can usually be easily treated before it turns into cancer, which is why regular Pap/HPV tests are so important. While condoms and dental dams don't offer complete protection, they can help lower your chances of getting HPV. CANCERS: High-risk HPV is more likely to cause cancer. For most people, the immune system is able to get rid of this type of infection. But some people develop a lasting infection. Over many years, the infection transforms normal cells into precancerous lesions or cancer. HPV infection causes nearly all cervical cancers. Of the cervical cancers related to HPV, about 70% are caused by 2 types: HPV-16 or HPV-18. Smoking may increase the risk of cervical cancer for women who have HPV. Although almost all cervical cancers are caused by HPV, it is important to remember that most genital HPV infections will not cause cancer. Next is oral cancer. HPV can cause cancer of the mouth and tongue. It can also cause cancer of the oropharynx. This is the middle part of the throat, from the tonsils to the tip of the voice box. These HPV-related cancers are increasing in men and women. Changes in sexual behavior, including an increase in oral sex, may be contributing to the increase. Also, HPV is associated with less common cancers, including anal cancer, vulvar and vaginal cancers in women, and penile cancer in men. NEW RESEARCH: Diane Harper, MD, MPH, MS, Senior Associate Director, MICHR, Professor, Family Medicine and Obstetrics and Gynecology at the University of Michigan talked about next steps for the new therapy: "The next steps for this is to figure out do we want to tweak the molecule to see if we can get a higher coverage rate? Or do we combine this with something else to be able to get a better cure, or potentially, such as in head and neck cancer, can we combine this with a chemotherapeutic agent in people who already have cancer to help their cure rates become even better." FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT: Ian Demsky, PR If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know~to seek or change treatments, please let us know by contacting Marjorie Bekaert Thomas at mthomas@ivanhoe.com  |
| Posted: 31 Jul 2019 06:59 AM PDT  Global HPV Testing & Pap Test Market, By Test Type ((HPV Testing), Follow-Up HPV Testing, Co-Testing, Primary HPV Testing, PAP Test)), Application (Cervical Cancer Screening, Vaginal Cancer Screening), End Users (Laboratories, Hospitals, Physicians' Offices Clinics), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends and Forecast to 2025 The Global HPV Testing & PAP Test Market is expected to reach USD 5840.7 million by 2025, growing at a CAGR of 6.6% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year2016, the base year of calculation is 2016 and the forecast period is 2018 to 2025. Request For Report Sample: http://www.marketgrowthanalysis.com/reports/sample/213 The Papanicolaou test is a method of screening out cervical that is utilized for detecting potentially pre-cancerous and cancerous processes in the cervix (opening of the womb or uterus). Irregular findings are usually followed up by more sensitive diagnostic tests and based on the need interventions that prevent progression to cervical cancer are implemented. The HPV test market is growing due to various factors such as growing population, rising number of cervical cancer cases, growing awareness of cervical cancer screening programs, and government initiative. The Cervical cancer remains is one of the major causes of cancer-related deaths in women. All such cancers originate from Human Papillomavirus (HPV) infection. However, the presence of HPV is not sufficient for disease; most women clear the virus without treatment. Various developments are made by the key players for the improvement of this test In April 2018, QIAGEN N.V. launched two novel liquid biopsy panels to evaluate circulating tumor cells (CTCs) in the growing field of research into molecular mechanisms in prostate and lung cancers. The AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit will be introduced at the American Association for Cancer Research (AACR) 2018. Thus, in the presence of all these factors , the market will grow rapidly. Market Segmentation: The global HPV testing & PAP test market is segmented based on test type, end user, application, and geographical segments. On the basis of test type, the market is classified into HPV testing, follow-up HPV testing, co-testing, primary HPV testing, PAP test. On the basis of application, the market is classified into cervical cancer screening, vaginal cancer screening. On the basis of end users, the market is segmented into laboratories, hospitals, physicians' offices and clinics. Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others. Get Complete ToC with Tables and Figures at : http://www.marketgrowthanalysis.com/reports/toc/213 Some of the major players operating in the global HPV testing & PAP test market are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., Arbor Vita Corporation, QiagenN. V.,Hologic, Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson, Qiagen N.V., Hologic Inc., and Company among others  |
| You are subscribed to email updates from "hpv test" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment